Ajanta Pharma Limited.
Healthcare · Pharmaceuticals
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.
- Market cap
- ₹43,980 cr
- P/E (TTM)
- 39.1
- P/B (latest)
- 9.7
- ROE (TTM)
- 23.3%
- ROCE (TTM)
- 30.6%
- Sales CAGR 3y
- 13.4%
- PAT CAGR 3y
- 21.6%
- Debt / equity
- 0.05x
- Promoter
- 63.5%
- Dividend yield
- 0.8%
- Size
- Mid
- Codes
- AJANTPHARM · 532331
₹3,557.5 · 29 Sept 2026
52-week ₹2,388.4 – ₹3,718.2 · ADTV ₹31.7 cr · price-only.
Sales and net profit by fiscal year, ₹ crore
Not in the Buoyant book: no house thesis or target is carried. Exchange masters, Tijori and the reference price feed as stated on each tab. All listed companies · NSE EQ